Cover Image
市場調查報告書

肽治療藥的全球市場:各用途、種類、廠商、部門的未來預測

Peptide Therapeutics Market By Application (Cancer, Cardiovascular Disorder, Metabolic Disorder, Respiratory Disorder, Pain, Dermatology), By Type (Generic, Innovative) By Type of Manufacturers (In-house, Outsourced), And Segment Forecasts, 2014 - 2025

出版商 Grand View Research, Inc. 商品編碼 544765
出版日期 內容資訊 英文 85 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
肽治療藥的全球市場:各用途、種類、廠商、部門的未來預測 Peptide Therapeutics Market By Application (Cancer, Cardiovascular Disorder, Metabolic Disorder, Respiratory Disorder, Pain, Dermatology), By Type (Generic, Innovative) By Type of Manufacturers (In-house, Outsourced), And Segment Forecasts, 2014 - 2025
出版日期: 2017年07月10日 內容資訊: 英文 85 Pages
簡介

本報告提供全球肽的市場相關分析,產品的特性和市場基本結構,主要的推動及市場的阻礙要素,整體市場規模趨勢預測 (過去3年、今後9年份),各用途、各醫藥品/製造商類型、給藥途徑、合成技術及各地區詳細趨勢,市場競爭環境 (市場佔有率、向心力等),主要企業簡介、業績等調查。

第1章 分析方法

第2章 摘要整理

第3章 肽治療藥市場:市場資料、趨勢、展望

  • 市場明細和範圍
  • 市場的推動要素分析
  • 市場的阻礙要素分析
  • 有力的市場機會
  • SWOT分析:各要因 (政治、法律,經濟,技術性要素)
  • 產業領域:波特的五力分析、模式

第4章 肽治療藥市場:各用途的預測值與趨勢分析

  • 各用途的市場趨勢分析
  • 癌症治療
    • 市場規模的預測值 (以金額為準,總計12年份)
  • 代謝異常症候群 (代謝症候群)
  • 心血管疾病 (CVD) 治療
  • 呼吸疾病治療
  • 腸胃管系 (GIT) 疾病治療
  • 感染疾病治療
  • 疼痛治療
  • 皮膚病治療
  • 中樞神經系統 (CNS) 治療
  • 腎臟病治療
  • 其他

第5章 肽治療藥市場:各種類的預測值與趨勢分析

  • 各種類的市場趨勢分析
  • 學名藥
  • 創新的醫藥品 (新藥)

第6章 肽治療藥市場:各製造商類型的預測值與趨勢分析

  • 各種類的市場趨勢分析
  • 內部型廠商
  • 外包型廠商

第7章 肽治療藥市場:給藥途徑的預測值與趨勢分析

  • 各給藥途徑的市場趨勢
  • 非口服給藥
  • 口服給藥
  • 肺內給藥
  • 粘膜給藥
  • 其他

第8章 肽治療藥市場:各合成技術的預測值與趨勢分析

  • 各技術的市場趨勢
  • SPPS (肽固相合成法)
  • LPPS (肽液相合成法)
  • 混合技術

第9章 肽治療藥市場:各地區的預測價值與趨勢分析

  • 各地區的市場佔有率 (最新值,預測值)
  • 北美 (美國,加拿大)
    • 市場規模的預測值 (以金額為準,總計12年份)
  • 歐洲 (英國,德國)
  • 亞太地區 (日本,中國,印度)
  • 南美 (巴西,墨西哥)
  • 中東、非洲 (南非)

第10章 競爭結構

  • 企業策略的組成架構
  • 市場參與企業
  • 企業簡介
目錄
Product Code: 978-1-68038-179-5

The global peptide therapeutics market is expected to reach USD 48.04 billion by 2025, according to a new report by Grand View Research, Inc. Increasing demand for efficient & rapid-acting therapeutics for treatment of cancer and other lifestyle-associated disorders, which result in lesser adverse effects, are anticipated to propel market growth.

Rising incidence of cancer calls for exploring and introducing other means of therapies and low-cost treatment alternatives. Moreover, growing base of geriatric population is expected to widen the consumer base by triggering incidence rate of target diseases such as cancer & diabetes, which are expected to drive the demand for peptide therapeutics.

Technological advancements in peptide manufacturing process is one of the major factors driving the market growth during the forecast period. Manufacturers and suppliers are focusing on the adoption of novel technologies to manufacture efficient drug molecules with low time and capital investment. Improvement in purification & automation process and less generation of waste is an additional factor attributing toward market growth

Further Key Findings From the Study Suggest:

Cancer held the largest market share in 2016 owing to increasing demand for alternative therapeutics over conventional treatment options. Peptides are being used as potential therapeutic agents in cancer treatment.

The generic drug segment is expected to showcase upward shift due to patent expiration of blockbuster peptides and supportive government initiatives pertaining to the introduction of generic class

Outsourced manufacturing is expected to grow at CAGR of 6.7% owing to requirements of complex procedures and shift in preference toward outsourcing, which helps in eliminating cost of production.

Route of administration including nasal and intradermal routes is expected to grow at a rapid pace owing to ease of usage and advantages over other routes of administration such as oral.

Hybrid technology is expected to spearhead the growth of this market. Benefits associated with this technology such as time conservation and ease of usage for both solid- and liquid-phase peptide synthesis are the key factors affirming growth.

North America held the largest share in terms of revenue in 2016 owing to higher level of awareness pertaining to genomics & proteomics products, well-established R&D infrastructure, and rising funding initiatives

Asia Pacific industry is expected to showcase lucrative growth over the forecast period with CAGR of 11.0%. Presence of established generic industry and API providers in this region coupled with growing economic stability in some of the countries is expected to propel market growth.

Some of the key players in the peptide therapeutics market include Eli Lilly and Company; Pfizer, Inc.; Amgen, Inc.; Takeda Pharmaceutical Company Limited; Teva Pharmaceuticals Industries Ltd.; Lonza Inc.; Sanofi; Bristol-Myers Squibb (BMS); AstraZeneca PLC; GlaxoSmithKline plc (GSK); Novartis AG; and Novo Nordisk A/S

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Country wise market: Base estimates
  • 1.2 Global market: CAGR calculation
  • 1.3 Region based segment share calculation
  • 1.4 Research Scope & Assumptions
  • 1.5 List of Data Sources
    • 1.5.1 Data for primary interviews, by sources
    • 1.5.2 Data for primary interviews, by region

Chapter 2 Executive Summary

  • 2.1 Market Snapshot

Chapter 3 Peptide Therapeutics Market Variables, Trends & Scope

  • 3.1 Market segmentation & scope
  • 3.2 Market Driver Analysis
    • 3.2.1 Increasing prevalence of cancer
    • 3.2.2 Rising incidences of metabolic disorder
    • 3.2.3 Presence of strong product pipeline portfolio
    • 3.2.4 Technological Advancement
  • 3.3 Market restraint analysis
    • 3.3.1 Stringent regulations
  • 3.4 Key Opportunities Prioritized
    • 3.4.1 Key opportunities prioritized
  • 3.5 Peptide Therapeutics Market - SWOT Analysis, By Factor (political & legal, economic and technological)
  • 3.6 Industry Analysis - Porter's

Chapter 4 Peptide Therapeutics Market: Application Estimates & Trend Analysis

  • 4.1 Peptide Therapeutics market: Application movement analysis
  • 4.2 Cancer
    • 4.2.1 Cancer market, 2014 - 2025 (USD Million)
  • 4.3 Metabolic
      • 4.3.1.1 Metabolic market, 2014 - 2025 (USD Million)
  • 4.4 Cardiovascular Disorder
      • 4.4.1.1 Cardiovascular Disorder market, 2014 - 2025 (USD Million)
  • 4.5 Respiratory
      • 4.5.1.1 Respiratory market, 2014 - 2025 (USD Million)
  • 4.6 GIT
      • 4.6.1.1 GIT market, 2014 - 2025 (USD Million)
  • 4.7 Anti-infection
      • 4.7.1.1 Anti-infection market, 2014 - 2025 (USD Million)
  • 4.8 Pain
      • 4.8.1.1 Pain market, 2014 - 2025 (USD Million)
  • 4.9 Dermatology
      • 4.9.1.1 Dermatology market, 2014 - 2025 (USD Million)
  • 4.10 CNS
      • 4.10.1.1 CNS market, 2014 - 2025 (USD Million)
  • 4.11 Renal
      • 4.11.1.1 Renal market, 2014 - 2025 (USD Million)
  • 4.12 Others
      • 4.12.1.1 Others market, 2014 - 2025 (USD Million)

Chapter 5 Peptide Therapeutics Market: Type Estimates & Trend Analysis

  • 5.1 Peptide Therapeutics market: Type movement analysis
  • 5.2 Generic
    • 5.2.1 Generic Market, 2014 - 2025 (USD Million)
  • 5.3 Innovative
    • 5.3.1 Innovative Market, 2014 - 2025 (USD Million)

Chapter 6 Peptide Therapeutics Market: Type of Manufacturers Estimates & Trend Analysis

  • 6.1 Peptide Therapeutics market: Type of Manufacturers movement analysis
  • 6.2 In-house
    • 6.2.1 In-house market, 2014 - 2025 (USD Million)
  • 6.3 Outsourced
    • 6.3.1 Outsourced market, 2014 - 2025 (USD Million)

Chapter 7 Peptide Therapeutics Market Route of Administration Estimates & Trend Analysis

  • 7.1 Peptide Therapeutics market: Route of Administration movement analysis
  • 7.2 Parenteral
    • 7.2.1 Parenteral market, 2014 - 2025 (USD Million)
  • 7.3 Oral
    • 7.3.1 Oral market, 2014 - 2025 (USD Million)
  • 7.4 Pulmonary
    • 7.4.1 Pulmonary market, 2014 - 2025 (USD Million)
  • 7.5 Mucosal
    • 7.5.1 Mucosal market, 2014 - 2025 (USD Million)
  • 7.6 Others
    • 7.6.1 Others market, 2014 - 2025 (USD Million)

Chapter 8 Peptide Therapeutics Market Synthesis Technology Estimates & Trend Analysis

  • 8.1 Peptide Therapeutics market: Synthesis Technology movement analysis
  • 8.2 Solid Phase Peptide Synthesis (SPPS)
    • 8.2.1 Solid Phase Peptide Synthesis (SPPS) market, 2014 - 2025 (USD Million)
  • 8.3 Liquid Phase Peptide Synthesis (LPPS)
    • 8.3.1 Liquid Phase Peptide Synthesis (LPPS) market, 2014 - 2025 (USD Million)
  • 8.4 Hybrid Technology
    • 8.4.1 Hybrid Technology market, 2014 - 2025 (USD Million)

Chapter 9 Peptide Therapeutics Market: Regional Estimates & Trend Analysis, by Source, Product, Application

  • 9.1 Peptide Therapeutics market share by region, 2016 & 2025
  • 9.2 North America
    • 9.2.1 North America Peptide Therapeutics market, 2014 - 2025 (USD Million)
    • 9.2.2 U.S.
      • 9.2.2.1 U.S. Peptide Therapeutics market, 2014 - 2025 (USD Million)
    • 9.2.3 Canada
      • 9.2.3.1 Canada Peptide Therapeutics market, 2014 - 2025 (USD Million)
  • 9.3 Europe
    • 9.3.1 Europe Peptide Therapeutics market, 2014 - 2025 (USD Million)
    • 9.3.2 UK
      • 9.3.2.1 UK Peptide Therapeutics market, 2014 - 2025 (USD Million)
    • 9.3.3 Germany
      • 9.3.3.1 Germany Peptide Therapeutics market, 2014 - 2025 (USD Million)
  • 9.4 Asia Pacific
    • 9.4.1 Asia Pacific Peptide Therapeutics market, 2014 - 2025 (USD Million)
    • 9.4.2 Japan
      • 9.4.2.1 Japan Peptide Therapeutics market, 2014 - 2025 (USD Million)
    • 9.4.3 China
      • 9.4.3.1 China Peptide Therapeutics market, 2014 - 2025 (USD Million)
    • 9.4.4 India
      • 9.4.4.1 India Peptide Therapeutics market, 2014 - 2025 (USD Million)
  • 9.5 Latin America
      • 9.5.1.1 Latin America Peptide Therapeutics market, 2014 - 2025 (USD Million)
    • 9.5.2 Brazil
      • 9.5.2.1 Brazil Peptide Therapeutics market, 2014 - 2025 (USD Million)
    • 9.5.3 Mexico
      • 9.5.3.1 Mexico Peptide Therapeutics market, 2014 - 2025 (USD Million)
  • 9.6 MEA
    • 9.6.1 MEA Peptide Therapeutics market, 2014 - 2025 (USD Million)
    • 9.6.2 South Africa
      • 9.6.2.1 South Africa Peptide Therapeutics market, 2014 - 2025 (USD Million)

Chapter 10 Competitive Landscape

  • 10.1 Strategy Framework
  • 10.2 Market Participation
  • 10.3 Company Profiles
    • 10.3.1 Bachem Holding AG
      • 10.3.1.1 Company overview
      • 10.3.1.2 Financial performance
      • 10.3.1.3 Product benchmarking
      • 10.3.1.4 Strategic initiatives
    • 10.3.2 Eli Lilly and Company
      • 10.3.2.1 Company overview
      • 10.3.2.2 Financial performance
      • 10.3.2.3 Product benchmarking
      • 10.3.2.4 Strategic initiatives
    • 10.3.3 Pfizer Inc.
      • 10.3.3.1 Company overview
      • 10.3.3.2 Financial performance
      • 10.3.3.3 Product benchmarking
      • 10.3.3.4 Strategic initiatives
    • 10.3.4 Amgen Inc.
      • 10.3.4.1 Company overview
      • 10.3.4.2 Financial performance
      • 10.3.4.3 Product benchmarking
      • 10.3.4.4 Strategic initiatives
    • 10.3.5 Takeda Pharmaceutical Company Limited
      • 10.3.5.1 Company overview
      • 10.3.5.2 Financial performance
      • 10.3.5.3 Product benchmarking
      • 10.3.5.4 Strategic initiatives
    • 10.3.6 Teva Pharmaceutical
      • 10.3.6.1 Company overview
      • 10.3.6.2 Financial performance
      • 10.3.6.3 Product benchmarking
      • 10.3.6.4 Strategic initiatives
    • 10.3.7 Lonza Inc.
      • 10.3.7.1 Company overview
      • 10.3.7.2 Financial performance
      • 10.3.7.3 Product benchmarking
      • 10.3.7.4 Strategic initiatives
    • 10.3.8 Sanofi
      • 10.3.8.1 Company overview
      • 10.3.8.2 Financial performance
      • 10.3.8.3 Product benchmarking
      • 10.3.8.4 Strategic initiatives
    • 10.3.9 Bristol-Myers Squibb(BMS)
      • 10.3.9.1 Company overview
      • 10.3.9.2 Financial performance
      • 10.3.9.3 Product benchmarking
      • 10.3.9.4 Strategic initiatives
    • 10.3.10 AstraZeneca PLC
      • 10.3.10.1 Company overview
      • 10.3.10.2 Financial performance
      • 10.3.10.3 Product benchmarking
      • 10.3.10.4 Strategic initiatives
    • 10.3.11 Glaxosmithkline (GSK)
      • 10.3.11.1 Company overview
      • 10.3.11.2 Financial performance
      • 10.3.11.3 Product benchmarking
      • 10.3.11.4 Strategic initiatives
    • 10.3.12 Novartis AG
      • 10.3.12.1 Company overview
      • 10.3.12.2 Financial performance
      • 10.3.12.3 Product benchmarking
      • 10.3.12.4 Strategic initiatives
    • 10.3.13 Novo Nordisk A/S
      • 10.3.13.1 Company overview
      • 10.3.13.2 Financial performance
      • 10.3.13.3 Product benchmarking
      • 10.3.13.4 Strategic initiatives

List of Tables

  • TABLE 1 Factors used in segment share estimation
  • TABLE 2 List of secondary data sources
  • TABLE 3 Primary interview details, by source
  • TABLE 4 Primary interview details, by region
  • TABLE 5 North America Peptide Therapeutics market, by application, 2014 - 2025 (USD Million)
  • TABLE 6 North America Peptide Therapeutics market, by type, 2014 - 2025 (USD Million)
  • TABLE 7 North America Peptide Therapeutics market, by type of manufacturers, 2014 - 2025 (USD Million)
  • TABLE 8 North America Peptide Therapeutics market, by route of administration, 2014 - 2025 (USD Million)
  • TABLE 9 North America Peptide Therapeutics market, synthesis technology, 2014 - 2025 (USD Million)
  • TABLE 10 U.S. Peptide Therapeutics market, by application, 2014 - 2025 (USD Million)
  • TABLE 11 U.S. Peptide Therapeutics market, by type, 2014 - 2025 (USD Million)
  • TABLE 12 U.S. Peptide Therapeutics market, by type of manufacturers, 2014 - 2025 (USD Million)
  • TABLE 13 U.S. Peptide Therapeutics market, by route of administration, 2014 - 2025 (USD Million)
  • TABLE 14 U.S. Peptide Therapeutics market, synthesis technology, 2014 - 2025 (USD Million)
  • TABLE 15 Canada Peptide Therapeutics market, by application, 2014 - 2025 (USD Million)
  • TABLE 16 Canada Peptide Therapeutics market, by type, 2014 - 2025 (USD Million)
  • TABLE 17 Canada Peptide Therapeutics market, by type of manufacturers, 2014 - 2025 (USD Million)
  • TABLE 18 Canada Peptide Therapeutics market, by route of administration, 2014 - 2025 (USD Million)
  • TABLE 19 Canada Peptide Therapeutics market, synthesis technology, 2014 - 2025 (USD Million)
  • TABLE 20 Europe Peptide Therapeutics market, by application, 2014 - 2025 (USD Million)
  • TABLE 21 Europe Peptide Therapeutics market, by type, 2014 - 2025 (USD Million)
  • TABLE 22 Europe Peptide Therapeutics market, by type of manufacturers, 2014 - 2025 (USD Million)
  • TABLE 23 Europe Peptide Therapeutics market, by route of administration, 2014 - 2025 (USD Million)
  • TABLE 24 Europe Peptide Therapeutics market, by synthesis technology, 2014 - 2025 (USD Million)
  • TABLE 25 UK Peptide Therapeutics market, by application, 2014 - 2025 (USD Million)
  • TABLE 26 UK Peptide Therapeutics market, by type, 2014 - 2025 (USD Million)
  • TABLE 27 UK Peptide Therapeutics market, by type of administration, 2014 - 2025 (USD Million)
  • TABLE 28 UK Peptide Therapeutics market, by route of administration, 2014 - 2025 (USD Million)
  • TABLE 29 UK Peptide Therapeutics market, by synthesis technology, 2014 - 2025 (USD Million)
  • TABLE 30 Germany Peptide Therapeutics market, by application, 2014 - 2025 (USD Million)
  • TABLE 31 Germany Peptide Therapeutics market, by type, 2014 - 2025 (USD Million)
  • TABLE 32 Germany Peptide Therapeutics market, by type of administration, 2014 - 2025 (USD Million)
  • TABLE 33 Germany Peptide Therapeutics market, by route of administration, 2014 - 2025 (USD Million)
  • TABLE 34 Germany Peptide Therapeutics market, by synthesis technology, 2014 - 2025 (USD Million)
  • TABLE 35 Asia Pacific Peptide Therapeutics market, by application, 2014 - 2025 (USD Million)
  • TABLE 36 Asia Pacific Peptide Therapeutics market, by type, 2014 - 2025 (USD Million)
  • TABLE 37 Asia Pacific Peptide Therapeutics market, by type of administration, 2014 - 2025 (USD Million)
  • TABLE 38 Asia Pacific Peptide Therapeutics market, by route of administration, 2014 - 2025 (USD Million)
  • TABLE 39 Asia Pacific Peptide Therapeutics market, by synthesis technology, 2014 - 2025 (USD Million)
  • TABLE 40 Japan Peptide Therapeutics market, by application, 2014 - 2025 (USD Million)
  • TABLE 41 Japan Peptide Therapeutics market, by type, 2014 - 2025 (USD Million)
  • TABLE 42 Japan Peptide Therapeutics market, by type of administration, 2014 - 2025 (USD Million)
  • TABLE 43 Japan Peptide Therapeutics market, by route of administration, 2014 - 2025 (USD Million)
  • TABLE 44 Japan Peptide Therapeutics market, by synthesis technology, 2014 - 2025 (USD Million)
  • TABLE 45 China Peptide Therapeutics market, by application, 2014 - 2025 (USD Million)
  • TABLE 46 China Peptide Therapeutics market, by type, 2014 - 2025 (USD Million)
  • TABLE 47 China Peptide Therapeutics market, by type of administration, 2014 - 2025 (USD Million)
  • TABLE 48 China Peptide Therapeutics market, by route of administration, 2014 - 2025 (USD Million)
  • TABLE 49 China Peptide Therapeutics market, by synthesis technology, 2014 - 2025 (USD Million)
  • TABLE 50 India Peptide Therapeutics market, by application, 2014 - 2025 (USD Million)
  • TABLE 51 India Peptide Therapeutics market, by type, 2014 - 2025 (USD Million)
  • TABLE 52 India Peptide Therapeutics market, by type of administration, 2014 - 2025 (USD Million)
  • TABLE 53 India Peptide Therapeutics market, by route of administration, 2014 - 2025 (USD Million)
  • TABLE 54 India Peptide Therapeutics market, by synthesis technology, 2014 - 2025 (USD Million)
  • TABLE 55 Latin America Peptide Therapeutics market, by application, 2014 - 2025 (USD Million)
  • TABLE 56 Latin America Peptide Therapeutics market, by type, 2014 - 2025 (USD Million)
  • TABLE 57 Latin America Peptide Therapeutics market, by type of administration, 2014 - 2025 (USD Million)
  • TABLE 58 Latin America Peptide Therapeutics market, by route of administration, 2014 - 2025 (USD Million)
  • TABLE 59 Latin America Peptide Therapeutics market, by synthesis technology, 2014 - 2025 (USD Million)
  • TABLE 60 Brazil America Peptide Therapeutics market, by application, 2014 - 2025 (USD Million)
  • TABLE 61 Brazil Peptide Therapeutics market, by type, 2014 - 2025 (USD Million)
  • TABLE 62 Brazil Peptide Therapeutics market, by type of administration, 2014 - 2025 (USD Million)
  • TABLE 63 Brazil Peptide Therapeutics market, by route of administration, 2014 - 2025 (USD Million)
  • TABLE 64 Brazil Peptide Therapeutics market, by synthesis technology, 2014 - 2025 (USD Million)
  • TABLE 65 Mexico America Peptide Therapeutics market, by application, 2014 - 2025 (USD Million)
  • TABLE 66 Mexico Peptide Therapeutics market, by type, 2014 - 2025 (USD Million)
  • TABLE 67 Mexico Peptide Therapeutics market, by type of administration, 2014 - 2025 (USD Million)
  • TABLE 68 Mexico Peptide Therapeutics market, by route of administration, 2014 - 2025 (USD Million)
  • TABLE 69 Mexico Peptide Therapeutics market, by synthesis technology, 2014 - 2025 (USD Million)
  • TABLE 70 MEA America Peptide Therapeutics market, by application, 2014 - 2025 (USD Million)
  • TABLE 71 MEA Peptide Therapeutics market, by type, 2014 - 2025 (USD Million)
  • TABLE 72 MEA Peptide Therapeutics market, by type of administration, 2014 - 2025 (USD Million)
  • TABLE 73 MEA Peptide Therapeutics market, by route of administration, 2014 - 2025 (USD Million)
  • TABLE 74 MEA Peptide Therapeutics market, by synthesis technology, 2014 - 2025 (USD Million)
  • TABLE 75 South Africa Peptide Therapeutics market, by application, 2014 - 2025 (USD Million)
  • TABLE 76 South Africa Peptide Therapeutics market, by type, 2014 - 2025 (USD Million)
  • TABLE 77 South Africa Peptide Therapeutics market, by type of administration, 2014 - 2025 (USD Million)
  • TABLE 78 South Africa Peptide Therapeutics market, by route of administration, 2014 - 2025 (USD Million)
  • TABLE 79 South Africa Peptide Therapeutics market, by synthesis technology, 2014 - 2025 (USD Million)

List of Figures

  • FIG. 1 Primary interviews, by sources
  • FIG. 2 Market summary
  • FIG. 3 Market trends & outlook
  • FIG. 4 Market segmentation & scope
  • FIG. 5 Market driver relevance analysis (Current & future impact)
  • FIG. 6 Market restraint relevance analysis (Current & future impact)
  • FIG. 7 Key opportunities prioritized
  • FIG. 8 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 9 Porter's Five Forces Analysis
  • FIG. 10 Peptide Therapeutics market, Application outlook: Key takeaways
  • FIG. 11 Peptide Therapeutics market: Application movement analysis
  • FIG. 12 Cancer market, 2014 - 2025 (USD Million)
  • FIG. 13 Metabolic market, 2014 - 2025 (USD Million)
  • FIG. 14 Cardiovascular Disorder market, 2014 - 2025 (USD Million)
  • FIG. 15 Respiratory market, 2014 - 2025 (USD Million)
  • FIG. 16 GIT market, 2014 - 2025 (USD Million)
  • FIG. 17 Anti-infection market, 2014 - 2025 (USD Million)
  • FIG. 18 Pain market, 2014 - 2025 (USD Million)
  • FIG. 19 Dermatology market, 2014 - 2025 (USD Million)
  • FIG. 20 CNS market, 2014 - 2025 (USD Million)
  • FIG. 21 Renal market, 2014 - 2025 (USD Million)
  • FIG. 22 Others market, 2014 - 2025 (USD Million)
  • FIG. 23 Peptide Therapeutics market, type outlook: Key takeaways
  • FIG. 24 Peptide Therapeutics market: Type movement analysis
  • FIG. 25 Generic market, 2014 - 2025 (USD Million)
  • FIG. 26 Innovative market, 2014 - 2025 (USD Million)
  • FIG. 27 Peptide Therapeutics market, Type of Manufacturers outlook: Key takeaways
  • FIG. 28 Peptide Therapeutics market: Type of Manufacturers movement analysis
  • FIG. 29 In-house market, 2014 - 2025 (USD Million)
  • FIG. 30 Outsourced market, 2014 - 2025 (USD Million)
  • FIG. 31 Peptide Therapeutics market, Route of Administration outlook: Key takeaways
  • FIG. 32 Peptide Therapeutics market: Route of Administration movement analysis
  • FIG. 33 Parental market, 2014 - 2025 (USD Million)
  • FIG. 34 Oral market, 2014 - 2025 (USD Million)
  • FIG. 35 Pulmonary market, 2014 - 2025 (USD Million)
  • FIG. 36 Mucosal market, 2014 - 2025 (USD Million)
  • FIG. 37 Others market, 2014 - 2025 (USD Million)
  • FIG. 38 Peptide Therapeutics market, Synthesis Technology outlook: Key takeaways
  • FIG. 39 Peptide Therapeutics market: Synthesis Technology movement analysis
  • FIG. 40 Solid Phase Peptide Synthesis (SPPS) market, 2014 - 2025 (USD Million)
  • FIG. 41 Liquid Phase Peptide Synthesis (LPPS) market, 2014 - 2025 (USD Million)
  • FIG. 42 Hybrid Technology market, 2014 - 2025 (USD Million)
  • FIG. 43 Regional market place: Key takeaways
  • FIG. 44 Regional outlook, 2016 & 2025
  • FIG. 45 Strategy framework
  • FIG. 46 Market participation and categorization
Back to Top